In Silico World:
a community
of practice

We believe that one effective way to accelerate adoption of in silico technologies is to establish a pre-competitive safe space where professionals working in academia, industry, regulators agencies, research hospitals, software houses, and contract research organisations can exchange information and establish best practices.


Community of Practice

> Join the community

The adoption of In Silico Trials is a disruptive change and, like all major changes, it encounters some resistance.

To overcome this resistance, we thought of a safe, pre-competitive space where all experts and practitioners from academia, industry and regulatory agencies can ask for advices, exchange information, develop best practices and discuss anything else that can make the use of In Silico Trials an accepted practice.

The community is configured like a forum where members can join teams and collaboratively work on shared goals, projects, concerns, problems or topics.

The community is invitation-only: in this way we assure that only experts with professional interest in in silico medicine have access to the channels and resources.


Community
initiatives

The practice of In Silico Trials is still far from being established. Most of the research so far has been conducted in academic laboratories and thus far from the needs of industrial users. This is why our community works to consolidate a set of industrial practices that make easier and reliable the development and use of In Silico Trials solutions.

In Silico World is currently supporting several initiatives in this area:

Good
Simulation
Practice (GSP)

> Discover more about the GSP Task Force

In close collaboration with the Avicenna Alliance, In Silico World community of practice hosts the consensus process to develop the so-called Good Simulation Practice.

The idea is to develop eventually something equivalent to the Good Clinical Practice defined by the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

A first step in this consensus process is the collection of regulatory documents published worldwide that might be relevant for this consensus process.

You can contribute by joining the GSP Task Force established by the Avicenna Alliance in collaboration with the Medical Device Innovation Consortium and the Food and Drugs Administration

 

> Browse GSP document collection

 

> Join the GSP Task Force

Scalability and Efficiency

> Join the scalability channel

In the frame of the European Centre of Excellence in Computational medicine, In Silico World is monitoring all use cases where computational scalability and/or computational efficiency are a bottleneck for the wider adoption of In Silico Trials.

CompBioMed offers free support to improve the scalability of your computational biomedicine solutions with high performance computers.

Are you struggling because your code cannot run in an acceptable time?
Perhaps you are trying to simulate over 1000 virtual patients?
Or do you need to perform some large-scale sensitivity analysis to get your solution certified by a regulatory authority?

Whatever is the reason, we can help.

Thanks to the funding of the European Commission, the CompBioMed Centre of Excellence in Computational Biomedicine now offers free support to organisations in their initial steps towards improving the scalability of existing computational biomedicine applications and deploying them on high performance computing resources.

A team of experts will answer your questions through the #scalability public channel on the In Silico World Community of Practice hosted on Slack.

Endorsed and supported by Mobilise-D, a project funded by the European Commission and various members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) through the Innovative Medicine Initiative (IMI), the #dHealth4Trials channel is a virtual space for discussion and exchange of good practices about the use of digital health technologies in regulatory clinical trials for the safety or efficacy evaluation of new drugs or new medical devices.

 

 

Best practices emerge from success stories

“Experts do need a safe place where to exchange best practices on the regulatory qualification of these emerging technologies; #dHealth4Trials channel is the answer,”

 

said Dr. Wim Darte, Regulatory Affairs at Novartis Pharma AG and co-lead with Prof Marco Viceconti of the Regulatory activities in the Mobilise-D project.

Indeed, the channel will take its first steps from the recent success story of Mobilise-D and its request for qualification advice to EMA for the use of wearable sensors to quantify digital mobility outcomes and their use as biomarkers in regulatory drug trials.

 

Accelerate the adoption of digital technologies

“The #dHealth4Trial’s channel will provide to all practitioners an online community of practice where pre-competitive information can be exchanged freely. We believe this is an essential step to accelerate the adoption of digital technologies in regulatory trials: this community of experts, in collaboration with experts from regulatory agencies worldwide, could develop good qualification practices for the qualification of digital health methodologies”

 

said Prof. Marco Viceconti, founder of In Silico World.

Community
Administrators

As our community keeps growing and recently reached 400 members, we felt the need to establish a small governance that reflects and represents its members.

This is why every channel in the community now has an administrator, who is invited to the private channel @Governance, where all admins will discuss and take decisions for the life of the community.

These are the Community Administrators:

 

  • Marco Viceconti, Alma Mater Studiorum – Università di Bologna, as Founder of the community and Admin of #GoodSimulationPractices and #Goals,

 

  • Roberta De Michele, Alma Mater Studiorum – Università di Bologna, as Community Manager and Admin of #General and #OffTopic

 

  • Alfons Hoekstra, University of Amsterdam, as Admin of #ist_solutions

 

  • Angel Alberich, CEO of QUIBIM, as Admin of #Cancer

 

  • Cristina Curreli, Alma Mater Studiorum – Università di Bologna, as Admin of #insilicomedicine_unibo

 

  • David Wifling, Leibniz Supercomputing Centre, as Admin of #CoDesign

 

  • Emily Lumley, University College London, as Admin of #CompBioMed-AHM

 

  • Giorgio Davico, Alma Mater Studiorum – Università di Bologna, as Admin of #dhealth4trials

 

  • Francesco Pappalardo, University of Catania, as Admin of #IST_Research_Projects

 

  • Giulia Russo, University of Catania, as Admin of #Stritvuad_UISS-TB

 

  • Marco Verdicchio, SURF Dutch Supercomputing Centre, as Admin of #CompBioMed-WP4